Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.695
-0.005 (-0.29%)
Jun 3, 2026, 11:20 AM EDT - Market open
Inhibikase Therapeutics Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Inhibikase Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $6.00. The average 1-year stock price forecast is 253.98% higher than the current stock price, while the lowest is $3.00 (+76.99%) and the highest is $8.00 (+371.98%).
Price Target: $6.00 (+253.98%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Inhibikase Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 5 | 6 | 6 | 6 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 5 | 6 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $8 | Buy | Reiterates | $8 | +371.98% | May 26, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $4 | Buy | Maintains | $4 | +135.99% | May 19, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $5 | Buy | Maintains | $5 | +194.99% | May 16, 2026 |
| Maxim Group | Maxim Group | Buy Maintains $8 | Buy | Maintains | $8 | +371.98% | May 15, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains $6 | Buy | Maintains | $6 | +253.98% | May 15, 2026 |
Financial Forecast
Revenue This Year
300.00K
Revenue Next Year
400.00K
from 300.00K
Increased by 33.33%
EPS This Year
-0.43
from -0.49
EPS Next Year
-0.46
from -0.43
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1.5M | ||
| Avg | 300,000 | ||
| Low | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | 566.7% | |
| Avg | 33.3% | |
| Low | -100.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.35 | ||
| Avg | -0.43 | ||
| Low | -0.53 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Financial forecast data provided by S&P Global Market Intelligence. The data is sourced from Wall Street analysts. Data sources.